Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder

키워드

참고문헌 (109)

1. Volkmar FR, "Autism and pervasive developmental disorders", J Child Psychol Psychiatry, 45, pp.135~170 (2004)
2. Leyfer OT, "Comorbid psychiatric disorders in children with autism: interview development and rates of disorders", J Autism Dev Disord, 36, pp.849~861 (2006)
3. Baio J., "Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14sites, United States, 2008", MMWR Surveill Summ, 61, pp.1~19 (2012)
4. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
5. Zuddas A., "Autism assessment tools in the transition from DSM-IV to DSM-5", Eur Child Adolesc Psychiatry, 22, pp.325~327 (2013)
6. Gonca Celik, "Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger’s Disorder", Clinical Psychopharmacology and Neuroscience, 9(3), pp.134~136 (2011), 대한정신약물학회
7. Currenti SA., "Understanding and determining the etiology of autism", Cell Mol Neurobiol, 30, pp.161~171 (2010)
8. Giacobini E., "Cholinergic foundations of Alzheimer's disease therapy", J Physiol Paris, 92, pp.283~287 (1998)
9. Karvat G, "Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism", Neuropsychopharmacology, 39, pp.831~840 (2014)
10. Ghaleiha A, "Galantamine efficacy and tolerability as an augmentative therapy in autistic children:A randomized, double-blind, placebo-controlled trial", J Psychopharmacol (2013)
11. Niederhofer H., "Treating autism pharmacologically: also tacrine might improve symptomatology in some cases", J Child Neurol, 22, pp.1054~ (2007)
12. Chez MG, "Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate", J Child Neurol, 19, pp.165~169 (2004)
13. Hertzman M., "Galantamine in the treatment of adult autism: a report of three clinical cases", Int J Psychiatry Med, 33, pp.395~398 (2003)
14. Nicolson R, "A prospective, open-label trial of galantamine in autistic disorder", J Child Adolesc Psychopharmacol, 16, pp.621~629 (2006)
15. Niederhofer H, "Galantamine may be effective in treating autistic disorder", BMJ, 325, pp.1422~ (2002)
16. Hardan AY, "A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder", J Child Adolesc Psychopharmacol, 12, pp.237~241 (2002)
17. Chez MG, "Donepezil hydrochloride: a double-blind study in autistic children", J Pediatr Neurol, 1, pp.83~88 (2003)
18. Handen BL, "Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures", J Child Adolesc Psychopharmacol, 21, pp.43~50 (2011)
19. Carlson GC., "Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders", Pharmacol Biochem Behav, 100, pp.850~854 (2012)
20. Sheldon AL, "The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention", Neurochem Int, 51, pp.333~355 (2007)
21. Fatemi SH, "Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices", Biol Psychiatry, 52, pp.805~810 (2002)
22. Yip J, "Decreased GAD67mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications", Acta Neuropathol, 113, pp.559~568 (2007)
23. Brune CW, "Family-Based Association Testing of OCD-associated SNPs of SLC1A1 in an autism sample", Autism Res, 1, pp.108~113 (2008)
24. Brown MS, "Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1)H-MRS study", Autism Res, 6, pp.1~10 (2013)
25. Ortinski PI, "Selective induction of astrocytic gliosis generates deficits in neuronal inhibition", Nat Neurosci, 13, pp.584~591 (2010)
26. Kim KC, "Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic Acid-exposed rat offspring", Mol Neurobiol, 49, pp.512~528 (2014)
27. Chez MG, "Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability", J Child Neurol, 22, pp.574~579 (2007)
28. Erickson CA, "A retrospective study of memantine in children and adolescents with pervasive developmental disorders", Psychopharmacology (Berl), 191, pp.141~147 (2007)
29. Niederhofer H., "Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism", J Clin Psychopharmacol, 27, pp.317~318 (2007)
30. Owley T, "A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders", J Child Adolesc Psychopharmacol, 16, pp.517~524 (2006)
31. Ghaleiha A, "Memantine as adjunctive treatment to risperidone in children with autistic disorder:a randomized, double-blind, placebo-controlled trial", Int J Neuropsychopharmacol, 16, pp.783~789 (2013)
32. Berry-Kravis E, "A pilot open label, single dose trial of fenobam in adults with fragile X syndrome", J Med Genet, 46, pp.266~271 (2009)
33. Jacquemont S, "Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056", Sci Transl Med, 3, pp.64ra1~ (2011)
34. Berry-Kravis EM, "Effects of STX209(arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial", Sci Transl Med, 4, pp.152ra127~ (2012)
35. Erickson CA, "STX209(Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study", J Autism Dev Disord, 44, pp.958~964 (2014)
36. Watanabe Y, "Effect of continuous intravenous infusion of secretin preparation (secrepan) in patients with hemorrhage from chronic peptic ulcer and acute gastric mucosal lesion (AGML)", Gastroenterol Jpn, 26(Suppl 3), pp.86~89 (1991)
37. Charlton CG, "Secretin modulation of behavioral and physiological functions in the rat", Peptides, 4, pp.739~742 (1983)
38. Fremeau RT Jr, "Secretin: specific binding to rat brain membranes", J Neurosci, 3, pp.1620~1625 (1983)
39. Horvath K, "Improved social and language skills after secretin administration in patients with autistic spectrum disorders", J Assoc Acad Minor Phys, 9, pp.9~15 (1998)
40. Toda Y, "Administration of secretin for autism alters dopamine metabolism in the central nervous system", Brain Dev, 28, pp.99~103 (2006)
41. Williams K, "Intravenous secretin for autism spectrum disorders (ASD)", Cochrane Database Syst Rev, 4, pp.CD003495~ (2012)
42. Lobmaier PP, "Naltrexone depot formulations for opioid and alcohol dependence: a systematic review", CNS Neurosci Ther, 17, pp.629~636 (2011)
43. Chamberlain RS, "A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism", Biol Psychiatry, 28, pp.773~793 (1990)
44. Symons FJ, "Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis", Ment Retard Dev Disabil Res Rev, 10, pp.193~200 (2004)
45. Campbell M, "Naltrexone in autistic children:behavioral symptoms and attentional learning", J Am Acad Child Adolesc Psychiatry, 32, pp.1283~1291 (1993)
46. Stein DJ, "Opioids: from physical pain to the pain of social isolation", CNS Spectr, 12, pp.669~670 (2007)
47. Cook MN., "Dulcan's Textbook of Child and Adolescent Psychiatry", AM J Psychiatry, 169, pp.541~542 (2012)
48. Bakermans-Kranenburg MJ, "A sociability gene? Meta-analysis of oxytocin receptor genotype effects in humans", Psychiatr Genet, 24, pp.45~51 (2014)
49. Landgraf R, "Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication", Front Neuroendocrinol, 25, pp.150~176 (2004)
50. Inoue T, "Structural organization of the human oxytocin receptor gene", J Biol Chem, 269, pp.32451~32456 (1994)
51. Gimpl G, "The oxytocin receptor system:structure, function, and regulation", Physiol Rev, 81, pp.629~683 (2001)
52. Wermter AK, "Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR)in the etiology of autistic disorders on high-functioning level", Am J Med Genet B Neuropsychiatr Genet, 153B, pp.629~639 (2010)
53. Campbell DB, "Association of oxytocin receptor (OXTR) gene variants with multiple phenotype domains of autism spectrum disorder", J Neurodev Disord, 3, pp.101~112 (2011)
54. Hollander E, "Oxytocin increases retention of social cognition in autism", Biol Psychiatry, 61, pp.498~503 (2007)
55. Guastella AJ, "Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders", Biol Psychiatry, 67, pp.692~694 (2010)
56. Andari E, "Promoting social behavior with oxytocin in high-functioning autism spectrum disorders", Proc Natl Acad Sci U S A, 107, pp.4389~4394 (2010)
57. Kosaka H, "Long-term oxytocin administration improves social behaviors in a girl with autistic disorder", BMC Psychiatry, 12, pp.110~ (2012)
58. Leckman JF., "Variations in maternal behavior--oxytocin and reward pathways--peripheral measures matter?!", Neuropsychopharmacology, 36, pp.2587~2588 (2011)
59. Churchland PS, "Modulating social behavior with oxytocin: how does it work? What does it mean?", Horm Behav, 61, pp.392~399 (2012)
60. Guastella AJ, "Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research", Psychoneuroendocrinology, 38, pp.612~625 (2013)
61. Levy SE, "Complementary and alternative medicine treatments for children with autism spectrum disorders", Child Adolesc Psychiatr Clin N Am, 17, pp.803~820 (2008)
62. Davis MP, "Use of complementary and alternative medicine by children in the United States", Arch Pediatr Adolesc Med, 157, pp.393~396 (2003)
63. Kim P, "Effects of Korean red ginseng extracts on neural tube defects and impairment of social interaction induced by prenatal exposure to valproic acid", Food Chem Toxicol, 51, pp.288~296 (2013)
64. Soden SE, "24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study", Clin Toxicol (Phila), 45, pp.476~481 (2007)
65. Barbaresi WJ, "The incidence of clinically diagnosed versus research-identified autism in Olmsted County, Minnesota, 1976-1997: results from a retrospective, population-based study", J Autism Dev Disord, 39, pp.464~470 (2009)
66. Desoto MC, "Sorting out the spinning of autism:heavy metals and the question of incidence", Acta Neurobiol Exp (Wars), 70, pp.165~176 (2010)
67. Blaurock-Busch E, "Toxic metals and essential elements in hair and severity of symptoms among children with autism", Maedica (Buchar), 7, pp.38~48 (2012)
68. Tamm C, "High susceptibility of neural stem cells to methylmercury toxicity:effects on cell survival and neuronal differentiation", J Neurochem, 97, pp.69~78 (2006)
69. Bellinger DC., "Very low lead exposures and children's neurodevelopment", Curr Opin Pediatr, 20, pp.172~177 (2008)
70. 임명호, "자폐 스펙트럼장애의 환경 요인", 소아 청소년 정신의학, 22(1), pp.3~9 (2011), 대한소아청소년 정신의학회
71. Lee BK, "A comparison of different lead biomarkers in their associations with lead-related symptom", Int Arch Occup Environ Health, 73, pp.298~304 (2000)
72. Dietrich KN, "Treatment of Lead-Exposed Children Clinical Trial Group. Effect of chelation therapy on the neuropsychological and behavioral development of lead- exposed children after school entry", Pediatrics, 114, pp.19~26 (2004)
73. Nataf R, "Porphyrinuria in childhood autistic disorder: implications for environmental toxicity", Toxicol Appl Pharmacol, 214, pp.99~108 (2006)
74. Adams JB, "Effect of a vitamin", mineral supplement on children and adults with autism, 2011, pp.11, 111~
75. Krajcovicova-Kudlackova M, "Plasma concentrations of selected antioxidants in autistic children and adolescents", Bratisl Lek Listy, 110, pp.247~250 (2009)
76. McGrath J, "Vitamin D:the neglected neurosteroid?", Trends Neurosci, 24, pp.570~572 (2001)
77. Cannell JJ., "Autism and vitamin D", Med Hypotheses, 70, pp.750~759 (2008)
78. Cui X, "Maternal vitamin D depletion alters neurogenesis in the developing rat brain", Int J Dev Neurosci, 25, pp.227~232 (2007)
79. Hayashi E., "Seasonal changes in sleep and behavioral problems in a pubescent case with autism", Psychiatry Clin Neurosci, 55, pp.223~224 (2001)
80. Cannell JJ., "Autism, will vitamin D treat core symptoms?", Med Hypotheses, 81, pp.195~198 (2013)
81. Golnik AE, "Complementary alternative medicine for children with autism: a physician survey", J Autism Dev Disord, 39, pp.996~1005 (2009)
82. Yehuda S, "Mediation of cognitive function by high fat diet following stress and inflammation", Nutr Neurosci, 8, pp.309~315 (2005)
83. James S, "Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)", Cochrane Database Syst Rev, (11), pp.CD007992~ (2011)
84. Richardson AJ, "Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit", hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum, 2000, pp.63, 1~9
85. Williams K, "No evidence yet to support omega-3 fatty acids as a treatment for autism", J Paediatr Child Health, 48, pp.534~536 (2012)
86. Berk M, "The promise of N-acetylcysteine in neuropsychiatry", Trends Pharmacol Sci, 34, pp.167~177 (2013)
87. Arakawa M, "N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology", Cerebellum, 6, pp.308~314 (2007)
88. Kau KS, "Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaineinduced drug seeking", Neuroscience, 155, pp.530~537 (2008)
89. Lushchak VI., "Glutathione homeostasis and functions:potential targets for medical interventions", J Amino Acids, 2012, pp.736837~ (2012)
90. Villagonzalo KA, "Oxidative pathways as a drug target for the treatment of autism", Expert Opin Ther Targets, 14, pp.1301~1310 (2010)
91. Hardan AY, "A randomized controlled pilot trial of oral N-acetylcysteine in children with autism", Biol Psychiatry, 71, pp.956~961 (2012)
92. Naviaux RK, "Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model", PLoS One, 8, pp.e57380~ (2013)
93. Abbracchio MP, "Purinergic signalling in the nervous system: an overview", Trends Neurosci, 32, pp.19~29 (2009)
94. Junger WG., "Immune cell regulation by autocrine purinergic signalling", Nat Rev Immunol, 11, pp.201~212 (2011)
95. Zhang Q, "Circulating mitochondrial DAMPs cause inflammatory responses to injury", Nature, 464, pp.104~107 (2010)
96. Harada K, "Extracellular ATP differentially modulates Toll-like receptor 4-mediated cell survival and death of microglia", J Neurochem, 116, pp.1138~1147 (2011)
97. Kaur M, "Suramin's development: what did we learn?", Invest New Drugs, 20, pp.209~219 (2002)
98. Singh K, "Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action", J Antibiot (Tokyo), 32, pp.630~645 (1979)
99. Dennis PB, "Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation", Curr Opin Genet Dev, 9, pp.49~54 (1999)
100. Troca-Marín JA, "An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome", J Neurosci, 31, pp.9445~9455 (2011)
101. Won H, "Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses", Front Mol Neurosci, 6, pp.19~ (2013)
102. Jeste SS, "Characterization of autism in young children with tuberous sclerosis complex", J Child Neurol, 23, pp.520~525 (2008)
103. Ehninger D, "Reversal of learning deficits in a Tsc2+", - mouse model of tuberous sclerosis, 2008, pp.14, 843~848
104. Tsai PT, "Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice", Nature, 488, pp.647~651 (2012)
105. Boosani CS, "PTEN modulators: a patent review", Expert Opin Ther Pat, 23, pp.569~580 (2013)
106. Butler MG, "Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations", J Med Genet, 42, pp.318~321 (2005)
107. Kwon CH, "Pten regulates neuronal arborization and social interaction in mice", Neuron, 50, pp.377~388 (2006)
108. Ning K, "Leptin-dependent phosphorylation of PTEN mediates actin restructuring and activation of ATPsensitive K+ channels", J Biol Chem, 284, pp.9331~9340 (2009)
109. Napoli E, "Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53", PLoS One, 7, pp.e42504~ (2012)